Key Highlights

  • Second quarter net loss was $51.0 million, or $0.34 per share, and cash stood at $225.1 million on June 30.
  • The quarterly report says management concluded substantial doubt exists about the company's ability to continue as a going concern.
  • Warrant exercises from July 1 through September 12 brought in about $115.0 million of gross proceeds at $2.50 per share.
  • Registrational myositis data are expected in mid-2027, with a first BLA submission planned for the second half of 2027.

Cabaletta Bio (NASDAQ:CABA) shares were trading near their 52-week low at USD 1.49 on October 19, 2026, up 5.67%. The clinical-stage biotechnology company develops the CAR T therapy rese-cel for autoimmune disease. Its latest quarterly report carries a going concern conclusion, while warrant exercises since June 30 have added about $115.0 million of gross proceeds. Three reputed brokers have updated their views since the August 13 results.

Brokerage context

Morgan Stanley reiterated a Buy rating on August 17 with a $13 target, and Citi maintained a Buy rating with a $10 target in early September. Wells Fargo kept an Equal Weight rating on September 1 with a $3 target. Two of the three ratings are positive and one is neutral, with targets spanning $3 to $13. At USD 1.49, the shares were trading below all three targets, and all three actions came after the company's second quarter 2026 report.

Cash position, going concern language and equity raised

Cabaletta reported a second quarter 2026 net loss of $51.0 million, or $0.34 per share, against $45.1 million, or $0.73, a year earlier. Research and development expense rose to $44.4 million from $37.6 million, while general and administrative expense eased to $7.6 million from $8.3 million. The accumulated deficit stood at $611.5 million.

Cash and cash equivalents were $225.1 million at June 30, up from $133.6 million at December 31, 2025. The company expects this cash to fund its operating plan into mid-2027. The quarterly report nonetheless states that management concluded substantial doubt exists about the company's ability to continue as a going concern, while noting that cash may be sufficient for at least twelve months from the issuance date. Cabaletta said it intends to raise more capital and that, without adequate financing, it might delay or discontinue product candidates.

Equity has been the main funding source. A May 2026 registered direct offering of 51,725,000 shares at $2.90 per share produced net proceeds of about $140.2 million. At-the-market sales brought $28.7 million of net proceeds in the first half, and a further $5.5 million after June 30. Authorized common shares were doubled to 600,000,000 on June 9.

Warrants from the June 2025 financing carried a $2.50 exercise price and expired on September 12. A September 14 filing said 46,011,900 were exercised from July 1 through expiration for about $115.0 million of gross proceeds, bringing total exercise proceeds to about $128.2 million.

Rese-cel progress across autoimmune indications

Rese-cel, a CD19-directed CAR T therapy, is being studied across rheumatology, neurology and dermatology. The registrational RESET-Myositis cohort has 17 patients, 14 with adult dermatomyositis and 3 with antisynthetase syndrome. The company said that at EULAR 2026, 8 of 10 evaluable adult patients would have met the registrational primary endpoint, and that all dermatomyositis responders held their responses for up to 1.5 years. Across all 17 patients, cytokine release syndrome was absent or Grade 1 and none had ICANS.

In systemic sclerosis, citing completed Phase 1/2 data and FDA feedback, Cabaletta plans a single-arm registrational study of about 25 patients with interstitial lung disease, using a 52-week forced vital capacity endpoint. Rese-cel also received FDA Regenerative Medicine Advanced Therapy designation for generalized myasthenia gravis.

Outlook: milestones and funding

Cabaletta expects to start the systemic sclerosis registrational study in the fourth quarter of 2026 and to report registrational RESET-Myositis data in mid-2027. It plans a first BLA submission for rese-cel in myositis in the second half of 2027, including juvenile dermatomyositis data, and sees potential eligibility for a priority review voucher. Based on FDA discussions, the BLA safety database is expected to include about 100 autoimmune patients. These are company expectations, and the company says funding remains needed.